Fierce Pharma

SEPTEMBER 1, 2024

With the heart failure (HF) patient population rapidly expanding, the timing is right for Bayer’s Kerendia (finerenone). | At the European Society of Cardiology (ESC) event, Bayer unveiled data from the 3 FINEARTS-HF trial that showed Kerendia reduced the risk of cardiovascular death, as well as well as first and recurrent HF events by 16% compared to placebo in patients with mildly reduced (HFmrEF) or preserved ejection fraction (HFpEF).

Patients 231

Patients 231

pharmaphorum

SEPTEMBER 1, 2024

Alnylam Pharma has been riding high since revealing top-line results from its HELIOS-B trial of vutrisiran in transthyretin-mediated amyloidosis (ATTR) – but a look at the full data seems to have disappointed investors.Shares in the company retreated after the presentation of the results at the European Society of Cardiology (ESC) conference, which confirmed a 28% reduction in the primary endpoint of deaths from any cause and recurrent cardiovascular events after at least 33 months of follow-up.

Pharma 112

Pharma 112

Pharmacy Times

SEPTEMBER 1, 2024

The exhaled breath condensate mask was able to successfully monitor and accurately detect breath for nitrate in patients with asthma or chronic obstructive pulmonary disease.

Patients 52

Patients 52

pharmaphorum

SEPTEMBER 1, 2024

Bayer presents Kerendia data in heart failure with preserved and mildly reduced LVEF at ESC, sparking debate about how it may fit into treatment.

93

93

Speaker: Kevin Burke

AI is reshaping marketing and sales, empowering professionals to work smarter, faster, and more effectively. This webinar will provide a practical introduction to AI, focusing on its current applications, transformative potential, and strategies for successful implementation in your organization. Using real-world examples and actionable insights, we’ll examine how businesses are leveraging AI to increase efficiency, enhance personalization, and drive measurable results.

Sales

PharmaTech

SEPTEMBER 1, 2024

Thermo Scientific’s columns offer fast run times, optimal separation efficiency, and reliable results.

52

52

Pharmaceutical Technology

SEPTEMBER 1, 2024

A large proportion of chronic heart failure (HF) patients are taking suboptimal doses of relevant medications.

Medical 52

Medical Patients 52

PharmaTech

SEPTEMBER 1, 2024

Charles Ross & Son Company has introduced the ROSS CDA-300 Dual Shaft Mixer, consisting of two agitators and a disperse with an open disc blade.

52

52

PharmaTech

SEPTEMBER 1, 2024

Freudenberg Medical’s new offerings include single-use Y-connector manifolds, tubing assemblies, and bottlecap assemblies, among others.

52

52